

CONTENTS

I. VIRAL RNA SYNTHESIS

1.1.	THE CORONAVIRUS REPLICASE: INSIGHTS INTO A SOPHISTICATED ENZYME MACHINERY	3
	John Ziebuhr	
1.2.	BIOCHEMICAL ASPECTS OF CORONAVIRUS REPLICATION	13
	Luis Enjuanes, Fernando Almazán, Isabel Sola, Sonia Zúñiga, Enrique Alvarez, Juan Reguera, and Carmen Capiscol	
1.3.	A PREVIOUSLY UNRECOGNIZED UNR STEM-LOOP STRUCTURE IN THE CORONAVIRUS 5' UNTRANSLATED REGION PLAYS A FUNCTIONAL ROLE IN REPLICATION	25
	Pinghua Liu, Jason J. Millership, Lichun Li, David P. Giedroc, and Julian L. Leibowitz	
1.4.	REGULATION OF CORONAVIRUS TRANSCRIPTION: VIRAL AND CELLULAR PROTEINS INTERACTING WITH TRANSCRIPTION-REGULATING SEQUENCES.....	31
	Sonia Zúñiga, Isabel Sola, Jose L. Moreno, Sara Alonso, and Luis Enjuanes	
1.5.	DEUBIQUITINATING ACTIVITY OF THE SARS-CoV PAPAIN-LIKE PROTEASE	37
	Naina Barretto, Dalia Jukneliene, Kiira Ratia, Zhongbin Chen, Andrew D. Mesecar, and Susan C. Baker	
1.6.	NUCLEOCAPSID PROTEIN EXPRESSION FACILITATES CORONAVIRUS REPLICATION	43
	Barbara Schelle, Nadja Karl, Burkhard Ludewig, Stuart G. Siddell, and Volker Thiel	

1.7.	NON STRUCTURAL PROTEINS 8 AND 9 OF HUMAN CORONAVIRUS 229E.....	49
	Rajesh Ponnusamy, Jeroen R. Mesters, John Ziebuhr, Ralf Moll, and Rolf Hilgenfeld	
1.8.	EFFECTS OF MUTAGENESIS OF MURINE HEPATITIS VIRUS NSP1 AND NSP14 ON REPLICATION IN CULTURE.....	55
	Lance D. Eckerle, Sarah M. Brockway, Steven M. Sperry, Xiaotao Lu, and Mark R. Denison	
1.9.	MUTATIONAL ANALYSIS OF MHV-A59 REPLICASE PROTEIN-NSP10.....	61
	Eric F. Donaldson, Amy C. Sims, Damon J. Deming, and Ralph S. Baric	
1.10.	THE NSP2 PROTEINS OF MOUSE HEPATITIS VIRUS AND SARS CORONAVIRUS ARE DISPENSABLE FOR VIRAL REPLICATION.....	67
	Rachel L. Graham, Amy C. Sims, Ralph S. Baric, and Mark R. Denison	
1.11.	MOLECULAR DISSECTION OF PORCINE REPRODUCTIVE AND RESPIRATORY VIRUS PUTATIVE NONSTRUCTURAL PROTEIN 2.....	73
	Kay S. Faaberg, Jun Han, and Yue Wang	
1.12.	DIFFERENTIAL ROLE OF N-TERMINAL POLYPROTEIN PROCESSING IN CORONAVIRUS GENOME REPLICATION AND MINIGENOME AMPLIFICATION.....	79
	Carmen Galán, Luis Enjuanes, and Fernando Almazán	
1.13.	IDENTIFICATION AND CHARACTERIZATION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS SUBGENOMIC RNAs.....	85
	Snawar Hussain, Ji'an Pan, Jing Xu, Yalin Yang, Yu Chen, Yu Peng, Ying Wu, Zhaoyang Li, Ying Zhu, Po Tien, and Deyin Guo	
1.14.	IDENTIFICATION AND CHARACTERIZATION OF A UNIQUE RIBOSOMAL FRAMESHIFTING SIGNAL IN SARS-CoV ORF3A.....	89
	Xiao X. Wang, Ying Liao, Sek M. Wong, and Ding X. Liu	
1.15.	ADP-RIBOSE-1"-PHOSPHATASE ACTIVITIES OF THE HUMAN CORONAVIRUS 229E AND SARS CORONAVIRUS X DOMAINS.....	93
	Ákos Putics, Jutta Slaby, Witold Filipowicz, Alexander E. Gorbalenya, and John Ziebuhr	

1.16.	NONSTRUCTURAL PROTEINS OF HUMAN CORONAVIRUS NL63	97
	Yvonne Piotrowski, Lia van der Hoek, Krzysztof Pyrc, Ben Berkhout, Ralf Moll, and Rolf Hilgenfeld	
1.17.	MHV-A59 ORF1A REPLICASE PROTEIN NSP7-NSP10 PROCESSING IN REPLICATION	101
	Damon J. Deming, Rachel L. Graham, Mark R. Denison, and Ralph S. Baric	
1.18.	STEM-LOOP 1 IN THE 5' UTR OF THE SARS CORONAVIRUS CAN SUBSTITUTE FOR ITS COUNTERPART IN MOUSE HEPATITIS VIRUS	105
	Hyojeung Kang, Min Feng, Meagan E. Schroeder, David P. Giedroc, and Julian L. Leibowitz	
1.19.	TRANSCRIPTIONAL REGULATION OF RNA3 OF INFECTIOUS BRONCHITIS VIRUS	109
	Soonjeon Youn, Ellen W. Collisson, and Carolyn E. Machamer	

II. PROTEIN SYNTHESIS, STRUCTURE, AND PROCESSING

2.1.	STRUCTURE, EXPRESSION, AND INTRACELLULAR LOCALIZATION OF THE SARS-CoV ACCESSORY PROTEINS 7a AND 7b	115
	Andrew Pekosz, Scott R. Schaecher, Michael S. Diamond, Daved H. Fremont, Amy C. Sims, and Ralph S. Baric	
2.2.	SUMOYLATION OF THE NUCLEOCAPSID PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS BY INTERACTION WITH UBC9	121
	Qisheng Li, Han Xiao, James P. Tam, and Ding X. Liu	
2.3.	IMPORTANCE OF MHV-CoV A59 NUCLEOCAPSID PROTEIN COOH-TERMINAL NEGATIVE CHARGES	127
	Valerie Bednar, Sandhya Verma, Andrew Blount, and Brenda G. Hogue	
2.4.	EXPRESSION AND STRUCTURAL ANALYSIS OF INFECTIOUS BRONCHITIS VIRUS NUCLEOPROTEIN	133
	Kelly-Anne Spencer and Julian A. Hiscox	
2.5.	MOUSE HEPATITIS VIRUS INFECTION ACTIVATES THE IRE1/XBP1 PATHWAY OF THE UNFOLDED PROTEIN RESPONSE	139
	John Bechill, Zhongbin Chen, Joseph W. Brewer, and Susan C. Baker	

2.6.	THE NUCLEAR LOCALIZATION SIGNAL OF THE PRRS VIRUS NUCLEOCAPSID PROTEIN MODULATES VIRAL REPLICATION <i>IN VITRO</i> AND ANTIBODY RESPONSE <i>IN VIVO</i>	145
	Changhee Lee, Douglas C. Hodgins, Jay G. Calvert, Siao-Kun Wan Welch, Rika Jolie, and Dongwan Yoo	
2.7.	SARS CORONAVIRUS ACCESSORY ORFs ENCODE LUXURY FUNCTIONS.....	149
	Matthew B. Frieman, Boyd Yount, Amy C. Sims, Damon J. Deming, Thomas E. Morrison, Jennifer Sparks, Mark Denison, Mark Heise, and Ralph S. Baric	
2.8.	PRODUCTION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINST THE NUCLEOCAPSID PROTEIN OF SARS-COV	153
	Ying Fang, Andrew Pekosz, Lia Haynes, Eric A. Nelson, and Raymond R. R. Rowland	
2.9.	MOUSE HEPATITIS CORONAVIRUS NUCLEOCAPSID PHOSPHORYLATION.....	157
	Tiana C. White and Brenda G. Hogue	

III. VIRAL ASSEMBLY AND RELEASE

3.1.	GENETIC AND MOLECULAR BIOLOGICAL ANALYSIS OF PROTEIN-PROTEIN INTERACTIONS IN CORONAVIRUS ASSEMBLY	163
	Paul S. Masters, Lili Kuo, Rong Ye, Kelley R. Hurst, Cheri A. Koetzner, and Bilan Hsue	
3.2.	NEW INSIGHTS ON THE STRUCTURE AND MORPHOGENESIS OF BERNE VIRUS	175
	Ana Garzón, Ana M. Maestre, Jaime Pignatelli, M. Teresa Rejas, and Dolores Rodríguez	
3.3.	ULTRASTRUCTURE OF SARS-CoV, FIPV, AND MHV REVEALED BY ELECTRON CRYOMICROSCOPY	181
	Benjamin W. Neuman, Brian D. Adair, Craig Yoshioka, Joel D. Quispe, Ronald A. Milligan, Mark Yeager, and Michael J. Buchmeier	
3.4.	ROLE OF MOUSE HEPATITIS CORONAVIRUS ENVELOPE PROTEIN TRANSMEMBRANE DOMAIN.....	187
	Ye Ye and Brenda G. Hogue	
3.5.	THE TRANSMEMBRANE DOMAIN OF THE INFECTIOUS BRONCHITIS VIRUS E PROTEIN IS REQUIRED FOR EFFICIENT VIRUS RELEASE.....	193
	Carolyn E. Machamer and Soonjeon Youn	

3.6.	VIROPORIN ACTIVITY OF SARS-CoV E PROTEIN	199
	Ying Liao, James P. Tam, and Ding X. Liu	
3.7.	EFFICIENT TRANSDUCTION OF DENDRITIC CELLS USING CORONAVIRUS-BASED VECTORS	203
	Klara K. Eriksson, Divine Makia, Reinhard Maier, Luisa Cervantes, Burkhard Ludewig, and Volker Thiel	

IV. VIRAL ENTRY

4.1.	INSIGHTS FROM THE ASSOCIATION OF SARS-CoV S-PROTEIN WITH ITS RECEPTOR, ACE2.....	209
	Wenhui Li, Hyeryun Choe, and Michael Farzan	
4.2.	ATTACHMENT FACTOR AND RECEPTOR ENGAGEMENT OF SARS CORONAVIRUS AND HUMAN CORONAVIRUS NL63.....	219
	Heike Hofmann, Andrea Marzi, Thomas Gramberg, Martina Geier, Krzysztof Pyrc, Lia van der Hoek, Ben Berkhout, and Stefan Pöhlmann	
4.3.	INTERACTIONS BETWEEN SARS CORONAVIRUS AND ITS RECEPTOR	229
	Fang Li, Wenhui Li, Michael Farzan, and Stephen C. Harrison	
4.4.	PROTEOLYSIS OF SARS-ASSOCIATED CORONAVIRUS SPIKE GLYCOPROTEIN.....	235
	Graham Simmons, Andrew J. Rennekamp and Paul Bates	
4.5.	FLUORESCENCE DEQUENCHING ASSAYS OF CORONAVIRUS FUSION.....	241
	Victor C. Chu, Lisa J. McElroy, Beverley E. Bauman, and Gary R. Whittaker	
4.6.	PORCINE ARTERIVIRUS ENTRY IN MACROPHAGES: HEPARAN SULFATE – MEDIATED ATTACHMENT, SIALOADHESIN-MEDIATED INTERNALIZATION, AND A CELL-SPECIFIC FACTOR MEDIATING VIRUS DISASSEMBLY AND GENOME RELEASE.....	247
	Peter L. Delputte and H. J. Nauwynck	
4.7.	ENHANCEMENT OF SARS-CoV INFECTION BY PROTEASES	253
	Shutoku Matsuyama, Makoto Ujike, Koji Ishii, Shuetsu Fukushi, Shigeru Morikawa, Masato Tashiro, and Fumihiro Taguchi	

4.8.	INCREASED VIRAL TITERS AND SUBTLE CHANGES IN PLAQUE MORPHOLOGY UPON PASSAGE OF SARS-CoV IN CELLS FROM DIFFERENT SPECIES	259
	Laura Gillim-Ross, Lindsay K. Heller, Emily R. Olivieri, and David E. Wentworth	
4.9.	HUMAN CORONAVIRUS 229E CAN USE CD209L (L-SIGN) TO ENTER CELLS	265
	Scott A. Jeffers, Erin M. Hemmila, and Kathryn V. Holmes	
4.10.	INTRACELLULAR TRANSPORT OF THE S PROTEINS OF CORONAVIRUSES	271
	Christel Schwegmann-Weßels, Xiaofeng Ren, and Georg Herrler	
4.11.	ANALYSIS OF SARS-CoV RECEPTOR ACTIVITY OF ACE2 ORTHOLOGS	277
	Emily R. Olivieri, Lindsey K. Heller, Laura Gillim-Ross, and David E. Wentworth	
4.12.	INTERACTION BETWEEN THE SPIKE PROTEIN OF HUMAN CORONAVIRUS NL63 AND ITS CELLULAR RECEPTOR ACE2	281
	Stefan Pöhlmann, Thomas Gramberg, Anja Wegele, Krzysztof Pyrc, Lia van der Hoek, Ben Berkhout, and Heike Hofmann	
4.13.	HUMAN ANGIOTENSIN - CONVERTING ENZYME 2 (ACE2) IS A RECEPTOR FOR HUMAN RESPIRATORY CORONAVIRUS NL63	285
	M. K. Smith, Sonia Tusell, Emily A. Travanty, Ben Berkhout, Lia van der Hoek, and Kathryn V. Holmes	
4.14.	MOLECULAR INTERACTIONS OF GROUP 1 CORONAVIRUSES WITH FELINE APN	289
	Sonia M. Tusell and Kathryn V. Holmes	
4.15.	PSEUDOTYPED VESICULAR STOMATITIS VIRUS FOR FUNCTIONAL ANALYSIS OF SARS CORONAVIRUS SPIKE PROTEIN	293
	Shuetsu Fukushi, Tetsuya Mizutani, Masayuki Saijo, Shutoku Matsuyama, Fumihiro Taguchi, Ichiro Kurane, and Shigeru Morikawa	
4.16.	SUBCELLULAR LOCALIZATION OF SARS-CoV STRUCTURAL PROTEINS	297
	Lisa A. Lopez, Ariel Jones, William D. Arndt, and Brenda G. Hogue	

4.17.	SPIKE GENE DETERMINANTS OF MOUSE HEPATITIS VIRUS HOST RANGE EXPANSION	301
	Willie C. McRoy and Ralph S. Baric	
4.18.	VIRION-LIPOSOME INTERACTIONS IDENTIFY A CHOLESTEROL-INDEPENDENT CORONAVIRUS ENTRY STAGE	305
	Joseph A. Boscarino, Jeffrey M. Goletz, and Thomas M. Gallagher	
4.19.	AVIAN INFECTIOUS BRONCHITIS VIRUS ENTERS CELLS VIA THE ENDOCYTIC PATHWAY	309
	Victor C. Chu, Lisa J. Mcelroy, A Damon Ferguson, Beverley E. Bauman, and Gary R. Whittaker	
4.20.	THREE-DIMENSIONAL RECONSTRUCTION OF THE NUCLEOLUS USING META-CONFOCAL MICROSCOPY IN CELLS EXPRESSING THE CORONAVIRUS NUCLEOPROTEIN	313
	Jae-Hwan You, Mark L. Reed, Brian K. Dove, and Julian A. Hiscox	
4.21.	DISSECTION OF THE FUSION MACHINE OF SARS-CORONAVIRUS	319
	Megan W. Howard, Brian Tripet, Michael G. Jobling, Randall K. Holmes, Kathryn V. Holmes, and Robert S. Hodges	
4.22.	CHARACTERIZATION OF PERSISTENT SARS-CoV INFECTION IN VERO E6 CELLS.....	323
	Tetsuya Mizutani, Shuetsu Fukushi, Masayuki Saijo, Ichiro Kurane, and Shigeru Morikawa	
4.23.	RECEPTOR-INDEPENDENT SPREAD OF A NEUROTROPIC MURINE CORONAVIRUS MHV-JHMV IN MIXED NEURAL CULTURE	327
	Keiko Nakagaki, Kazuhide Nakagaki, and Fumihiro Taguchi	
4.24.	RECEPTOR-INDEPENDENT INFECTION OF MOUSE HEPATITIS VIRUS: ANALYSIS BY SPINOCULATION	331
	Rie Watanabe, Kazumitsu Suzuki, and Fumihiro Taguchi	
4.25.	SARS-CoV, BUT NOT HCoV-NL63, UTILIZES CATHEPSINS TO INFECT CELLS: VIRAL ENTRY	335
	I-Chueh Huang, Berend Jan Bosch, Wenhui Li, Michael Farzan, Peter M. Rottier, and Hyeryun Choe	

V. PATHOGENESIS OF NON-HUMAN CORONAVIRUSES

5.1.	CORONAVIRUS IMMUNITY: FROM T CELLS TO B CELLS.....	341
	Cornelia C. Bergmann, Chandran Ramakrishna, J. M. Gonzales, S.I. Tschen, and Stephan A. Stohlman	
5.2.	RAT CORONAVIRUS INFECTION OF PRIMARY RAT ALVEOLAR EPITHELIAL CELLS	351
	Tanya A. Miura, Jieru Wang, Robert J. Mason, and Kathryn V. Holmes	
5.3.	INFECTIOUS BRONCHITIS CORONAVIRUS INDUCES CELL-CYCLE PERTURBATIONS.....	357
	Brian K. Dove, Katrina Bicknell, Gavin Brooks, Sally Harrison, and Julian A. Hiscox	
5.4.	GENES 3 AND 5 OF INFECTIOUS BRONCHITIS VIRUS ARE ACCESSORY PROTEIN GENES	363
	Paul Britton, Rosa Casais, Teri Hodgson, Marc Davis, and Dave Cavanagh	
5.5.	NKG2D SIGNALING AND HOST DEFENSE AFTER MOUSE HEPATITIS VIRUS INFECTION OF THE CENTRAL NERVOUS SYSTEM.....	369
	Kevin B. Walsh, Melissa B. Lodoen, Lewis L. Lanier, and Thomas E. Lane	
5.6.	MURINE HEPATITIS VIRUS STRAIN 1 AS A MODEL FOR SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (SARS).....	373
	Nadine DeAlbuquerque, Ehtesham Baig, Max Xuezhong, Itay Shalev, M. James Phillips, Marlena Habal, Julian Leibowitz, Ian McGilvray, Jagdish Butany, Eleanor Fish, and Gary Levy	
5.7.	PERSISTENT CORONAVIRUS INFECTION OF PROGENITOR OLIGODENDROCYTES.....	379
	Yin Liu and Xuming Zhang	
5.8.	CD8+ T-CELL PRIMING DURING A CENTRAL NERVOUS SYSTEM INFECTION WITH MOUSE HEPATITIS VIRUS	385
	Katherine C. MacNamara and Susan R. Weiss	
5.9.	ANTIBODY-MEDIATED VIRUS CLEARANCE FROM NEURONS OF RATS INFECTED WITH HEMAGGLUTININATING ENCEPHALOMYELITIS VIRUS	391
	Norio Hirano, Hideharu Taira, Shigehiro Sato, Tsutomu Hashikawa, and Koujiro Tohyama	

5.10.	DEVELOPING BIOINFORMATIC RESOURCES FOR CORONAVIRUSES	395
	Susan C. Baker, Dalia Jukneliene, Anjan Purkayastha, Eric E. Snyder, Oswald R. Crasta, Michael J. Czar, Joao C. Setubal, and Bruno W. Sobral	
5.11.	AUTOANTIBODIES EXACERBATE THE SEVERITY OF MHV-INDUCED ENCEPHALITIS	399
	Renaud Burrer, Matthias G. von Herrath, Tom Wolfe, Julia D. Rempel, Antonio Iglesias, and Michael J. Buchmeier	
5.12.	ANALYSIS OF THE N PROTEIN IN FELINE CORONAVIRUS STRAINS IN ITALY	403
	Mara Battilani, Ambra Foschi, Alessandra Scagliarini, Sara Ciulli, Santino Prosperi, and Luigi Morganti	
5.13.	DIFFERENTIAL INDUCTION OF PROINFLAMMATORY CYTOKINES IN PRIMARY MOUSE ASTROCYTES AND MICROGLIA BY CORONAVIRUS INFECTION	407
	Dongdong Yu and Xuming Zhang	
5.14.	PREFERENTIAL INFECTION OF MATURE DENDRITIC CELLS BY THE JHM STRAIN OF MOUSE HEPATITIS VIRUS	411
	Haixia Zhou and Stanley Perlman	
5.15.	ROLE OF THE REPLICASE GENE OF MURINE CORONAVIRUS JHM STRAIN IN HEPATITIS	415
	Sonia Navas-Martín, Maarten Brom, and Susan R. Weiss	
5.16.	IDENTIFICATION OF THE RECEPTOR FOR FGL2 AND IMPLICATIONS FOR SUSCEPTIBILITY TO MOUSE HEPATITIS VIRUS (MHV-3)-INDUCED FULMINANT HEPATITIS	421
	Hao Liu, Li Zhang, Myron Cybulsky, Reg Gorczynski, Jennifer Crookshank, Justin Manuel, David Grant, and Gary Levy	
 VI. PATHOGENESIS OF ARTERIVIRUSES AND TOROVIRUSES		
6.1.	EQUINE VIRAL ARTERITIS	429
	N. James MacLachlan and Udeni B. Balasuriya	
6.2.	USE OF A PRRSV INFECTIOUS CLONE TO EVALUATE <i>IN VITRO</i> QUASISPECIES EVOLUTION	435
	Susan K. Schommer and Steven B. Kleiboeker	

6.3.	GAMMA-INTERFERON INVOLVEMENT IN THE PATHOGENESIS OF LACTATE DEHYDROGENASE-ELEVATING VIRUS INFECTION	439
	Andrei Musaji, Dominique Markine-Goriaynoff, Stéphanie Franquin, Gaëtan Thirion, Thao Le Thi Phuong, and Jean-Paul Coutelier	
6.4.	REPLICATION AND EXPRESSION ANALYSIS OF PRRSV DEFECTIVE RNA	445
	Jun Han, Kelly M. Burkhart, Eric M. Vaughn, Michael B. Roof, and Kay S. Faaberg	
6.5.	EFFICACY OF AN INACTIVATED PRRSV VACCINE: INDUCTION OF VIRUS-NEUTRALIZING ANTIBODIES AND PARTIAL VIROLOGICAL PROTECTION UPON CHALLENGE.....	449
	Gerald Misinzo, Peter L. Delputte, Peter Meerts, Christa Drexler, and Hans J. Nauwynck	
 VII. PATHOGENESIS OF HUMAN CORONAVIRUSES		
7.1.	SARS AND OTHER CORONAVIRUSES IN HUMANS AND ANIMALS	457
	Leo L. M. Poon	
7.2.	ANIMAL MODELS FOR SARS	463
	Anjeanette Roberts and Kanta Subbarao	
7.3.	HCoV-OC43-INDUCED APOPTOSIS OF MURINE NEURONAL CELLS	473
	Hélène Jacomy and Pierre J. Talbot	
7.4.	INFECTION OF HUMAN AIRWAY EPITHELIA BY SARS CORONAVIRUS IS ASSOCIATED WITH ACE2 EXPRESSION AND LOCALIZATION	479
	Hong Peng Jia, Dwight C. Look, Melissa Hickey, Lei Shi, Lecia Pewe, Jason Netland, Michael Farzan, Christine Wohlford-Lenane, Stanley Perlman, and Paul B. McCray, Jr.	
7.5.	HUMAN CORONAVIRUS NL63 INFECTION IS ASSOCIATED WITH CROUP	485
	Lia van der Hoek, Klaus Sure, Gabriele Ihorst, Alexander Stang, Krzysztof Pyrc, Maarten F. Jebbink, Gudula Petersen, Johannes Forster, Ben Berkhout, and Klaus Überla	
7.6.	A SARS-CoV-SPECIFIC PROTEIN ENHANCES VIRULENCE OF AN ATTENUATED STRAIN OF MOUSE HEPATITIS VIRUS.....	493
	Lecia Pewe, Haixia Zhou, Jason Netland, Chandra Tangadu, Heidi Olivares, Lei Shi, Dwight Look, Thomas Gallagher, and Stanley Perlman	

7.7.	GENETIC EVOLUTION OF HUMAN CORONAVIRUS OC43 IN NEURAL CELL CULTURE.....	499
	Julien R. St-Jean, Marc Desforbes, and Pierre J. Talbot	
7.8.	SYNERGISTIC INHIBITION OF SARS-CORONAVIRUS REPLICATION BY TYPE I AND TYPE II IFN.....	503
	Eric C. Mossel, Bruno Sainz, Jr., Robert F. Garry, and C.J. Peters	
7.9.	<i>MUSTELA VISON</i> ACE2 FUNCTIONS AS A RECEPTOR FOR SARS-CORONAVIRUS	507
	Lindsay K. Heller, Laura Gillim-Ross, Emily R. Olivieri, and David E. Wentworth	
7.10.	HCoV-229E INFECTS AND ACTIVATES MONOCYTES.....	511
	Marc Desforbes, Tina Miletti, Mylène Gagnon, and Pierre J. Talbot	
7.11.	PATHOLOGICAL AND VIROLOGICAL ANALYSES OF SEVERE ACUTE RESPIRATORY SYNDROME–ASSOCIATED CORONAVIRUS INFECTIONS IN EXPERIMENTAL ANIMALS.....	515
	Noriyo Nagata, Naoko Iwata, Hideki Hasegawa, Yasuko Asahi-Ozaki, Yuko Sato, Ayako Harashima, Shigeru Morikawa, Masayuki Saijo, Shigeyuki Itamura, Takehiko Saito, Takato Odagiri, Masato Tashiro, Yasushi Ami, and Tetsutaro Sata	
7.12.	IDENTIFICATION OF FERRET ACE2 AND ITS RECEPTOR FUNCTION FOR SARS-CORONAVIRUS	519
	Aya Zamoto, Fumihiko Taguchi, Shuetsu Fukushima, Shigeru Morikawa, and Yasuko K. Yamada	
7.13.	HUMAN CORONAVIRUS-NL63 INFECTION IS NOT ASSOCIATED WITH ACUTE KAWASAKI DISEASE.....	523
	S.C. Baker, C. Shimizu, H. Shike, F. Garcia, L. van der Hoek, T.W. Kuijper, S.L. Reed, A.H. Rowley, S.T. Shulman, H.K.B. Talbot, J.V. Williams, and J.C. Burns	
7.14.	TOWARD THE DEVELOPMENT OF AN INFECTIOUS cDNA CLONE OF A HUMAN ENTERIC CORONAVIRUS.....	527
	Hongqing Zhu, Yin Liu, Yingyun Cai, Dongdong Yu, Yinghui Pu, Laura Harmon, and Xuming Zhang	
7.15.	HCoV-OC43–INDUCED ENCEPHALITIS IS IN PART IMMUNE-MEDIATED.....	531
	Noah Butler, Lecia Pewe, Kathryn Trandem, and Stanley Perlman	

7.16.	SARS CoV REPLICATION AND PATHOGENESIS IN HUMAN AIRWAY AIRWAY EPITHELIAL CULTURES	535
	Amy C. Sims, Boyd Yount, Susan E. Burkett, Ralph S. Baric, and Raymond J. Pickles	
7.17.	IMMUNOGENICITY OF SARS-CoV: THE RECEPTOR-BINDING DOMAIN OF S PROTEIN IS A MAJOR TARGET OF NEUTRALIZING ANTIBODIES	539
	Yuxian He	
7.18.	GLIA EXPRESSION OF MHC DURING CNS INFECTION BY NEUROTROPIC CORONAVIRUS	543
	Karen E. Malone, Chandran Ramakrishna, J.-M. Gonzalez, Stephan A. Stohlman, and Cornelia C. Bergmann	
7.19.	RESURRECTION OF AN “EXTINCT” SARS-CoV ISOLATE GD03 FROM LATE 2003	547
	Timothy Sheahan, Damon Deming, Eric Donaldson, Raymond Pickles, and Ralph Baric	

VIII. VACCINES, ANTIVIRAL DRUGS, AND DIAGNOSTICS

8.1.	SARS CORONAVIRUS VACCINE DEVELOPMENT	553
	Ralph S. Baric, Timothy Sheahan, Damon Deming, Eric Donaldson, Boyd Yount, Amy C. Sims, Rhonda S. Roberts, Matthew Frieman, and Barry Rockx	
8.2.	DEVELOPMENT OF VACCINES AND PASSIVE IMMUNOTHERAPY AGAINST SARS CORONAVIRUS USING MOUSE AND SCID-PBL/hu MOUSE MODELS	561
	Masaji Okada, Yuji Takemoto, Yoshinobu Okuno, Satomi Hashimoto, Yukari Fukunaga, Takao Tanaka, Yoko Kita, Sechiko Kuwayama, Yumiko Muraki, Noriko Kanamaru, Hiroko Takai, Chika Okada, Yayoi Sakaguchi, Izumi Furukawa, Kyoko Yamada, Miwa Izumiya, Shigeto Yoshida, Makoto Matsumoto, Tetsuo Kase, J.S.M. Peiris, Daphne E. deMello, Pei-Jer Chen, Naoki Yamamoto, Yoshiyuki Yoshinaka, Tatsuji Nomura, Isao Ishida, Shigeru Morikawa, Masato Tashiro, and Mitsunori Sakatani	
8.3.	INHIBITION AND ESCAPE OF SARS-CoV TREATED WITH ANTISENSE MORPHOLINO OLIGOMERS	567
	Benjamin W. Neuman, David A. Stein, Andrew D. Kroeker, Hong M. Richard K. Bestwick, Patrick L. Iversen, and Michael J. Buchmeier	

8.4.	VALIDATION OF CORONAVIRUS E PROTEINS ION CHANNELS AS TARGETS FOR ANTIVIRAL DRUGS	573
	Lauren Wilson, Peter Gage, and Gary Ewart	
8.5.	IDENTIFICATION OF ESSENTIAL GENES AS A STRATEGY TO SELECT A SARS CANDIDATE VACCINE USING A SARS-CoV INFECTIOUS cDNA.....	579
	Fernando Almazán, Marta L. De Diego, Carmen Galán, Enrique Álvarez, and Luis Enjuanes	
8.6.	STRUCTURE AND DYNAMICS OF SARS CORONAVIRUS MAIN PROTEINASE (M ^{PRO}).....	585
	Rolf Hilgenfeld, Kanchan Anand, Jeroen R. Mesters, Zihe Rao, Xu Shen, Hualiang Jiang, Jinzhi Tan, and Koen H.G. Verschueren	
8.7.	HIGHLY ATTENUATED VACCINIA VIRUS DIs AS A POTENTIAL SARS VACCINE.....	593
	Koji Ishii, Hideki Hasegawa, Noriyo Nagata, Tetsuya Mizutani, Shigeru Morikawa, Masato Tashiro, Tetsuro Suzuki, Fumihiko Taguchi, Toshitada Takemori, Tatsuo Miyamura, and Yasuko Tsunetsugu-Yokota	
8.8.	<i>RENILLA</i> LUCIFERASE AS A REPORTER TO ASSESS SARS-CoV mRNA TRANSCRIPTION REGULATION AND EFFICACY OF ANTI-SARS-CoV AGENTS	597
	Rhonda S. Roberts, Boyd L. Yount, Amy C. Sims, Susan Baker, and Ralph S. Baric	
8.9.	VIRUCIDAL EFFECT OF A NEWLY DEVELOPED NICKEL ALLOY ON MOUSE CORONAVIRUS.....	601
	Norio Hirano and Takenori Nakayama	
8.10.	CONSTRUCTION OF A FULL-LENGTH cDNA INFECTIOUS CLONE OF A EUROPEAN-LIKE TYPE 1 PRRSV ISOLATED IN THE U.S.....	605
	Ying Fang, Kay S. Faaberg, Raymond R.R. Rowland, J. Christopher-Hennings, Asit K. Pattnaik, Fernando Osorio, and Eric A. Nelson	
8.11.	IDENTIFICATION AND EVALUATION OF CORONAVIRUS REPLICASE INHIBITORS USING A REPLICON CELL LINE	609
	Elke Scandella, Klara K. Eriksson, Tobias Hertzog, Christian Drosten, Lili Chen, Chunshan Gui, Xiaomin Luo, Jianhua Shen, Xu Shen, Stuart G. Siddell, Burkhard Ludewig, Hualiang Jiang, Stephan Günther, and Volker Thiel	
	INDEX	615

The Nidoviruses

Toward Control of SARS and other Nidovirus Diseases

(Eds.) S. Perlman; K.V. Holmes

2006, XXXVII, 618 p., 221 illus., 3 in colour, Hardcover

ISBN: 978-0-387-26202-4